CONGRESS COVERAGE ASCO/EHA 2021 – Focus on Multiple Myeloma

The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?

June 23, 2021
Maria Victoria Mateos, MD, PhD Aptitude Health 2020 multiple myeloma

Faculty Chair

María Victoria Mateos, MD, PhD

University of Salamanca, Spain

Faculty Members

Irene Ghobrial, MD
Dana-Farber Cancer Institute, Boston, MA, US

Niels van de Donk, MD, PhD
Amsterdam University Medical Center, Amsterdam, the Netherlands

Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and Sorbonne University, Paris, France

Sagar Lonial, MD, FACP
Emory University School of Medicine, Atlanta, GA, US

Hermann Einsele, MD, FRCP
Medizinische Klinik und Poliklinik II, Würzburg, Germany

Gareth Morgan, MD, PhD
NYU Langone Medical Center, New York, NY, US

Sample Report

Start discovering the insights

View Report


  • First Line (1): Smoldering and Transplant-Ineligible Multiple Myeloma
  • First Line (2): Induction in Transplant-Eligible Multiple Myeloma
  • First Line (3): Maintenance and MRD
  • R/R MM: First and Second Relapse
  • Triple-Refractory R/R MM: Novel Agents
  • Triple-Refractory R/R MM: Antibodies and Bispecifics
  • Triple-Refractory R/R MM: CAR Ts

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.